<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989780</url>
  </required_header>
  <id_info>
    <org_study_id>JBCRG-M04</org_study_id>
    <nct_id>NCT01989780</nct_id>
  </id_info>
  <brief_title>Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer</brief_title>
  <acronym>BOOSTER</acronym>
  <official_title>Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive HER2-negative Breast Cancer -BOOSTER Trial, a Multicenter Randomized Phase II Study-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate optimal usage of bevacizumab to compare which is better, continuing bevacizumab
      and paclitaxel or switching to hormonal maintenance therapy followed by
      bevacizumab+paclitaxel after induction therapy of bevacizumab+paclitaxel.

      To examine biomarkers such as monitoring markers of study treatment as exploratory analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter, randomized Phase II study of patients with advanced or metastatic estrogen
      receptor-positive human epidermal receptor type 2-negative breast cancer aims to compare two
      treatment strategies following induction therapy with 4-6 cycles of the combined use of
      weekly paclitaxel (wPTX) and bevacizumab (BV). In arm A, wPTX+BV is continued, while in arm
      B, wPTX is switched to maintenance endocrine therapy (hormone+BV) until disease progression,
      followed by wPTX+BV re-induction. The primary endpoint is time to failure of strategy, which
      is the time from randomization to a qualifying event (addition of a new agent not in the
      primary regimen, progressive disease during or after planned therapy, or death).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to failure of strategy (TFS)</measure>
    <time_frame>3.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2y Overall Survival rate</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>3.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>3.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker(IMPACT assay Chips, whole blood, tumor tissue, Serum)</measure>
    <time_frame>3.5years</time_frame>
    <description>vascular endothelial growth factor(VEGF)-A, VEGFR-2, VEGF-C, platelet derived growth factor(PDGF)-C, Soluble fms-like tyrosine kinase-1, VEGFR-3, Interleukin(IL)-8, Basic Fibroblast Growth Factor(FGFb), placental growth factor(PLGF), E-Selectin, intercellular adhesion molecule(ICAM)-1, neuropilin of Tumor tissue, single nucleotide polymorphism(SNP):VEGFR-1 and VEGF of whole blood DNA, angiotensin(ANG) and Apelin of serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety(Collection of adverse events)</measure>
    <time_frame>3.5years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weekly paclitaxel + bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weekly paclitaxel + bevacizumab followed by hormone therapy(Treatment of physician's choice)* + bevacizumab then back to weekly paclitaxel + bevacizumab
* Letrozole, Anastrozole, Exemestane, Fulvestrant, Goserelin, leuprorelin or LHRH Analogs + Aromatase inhibitors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprorelin</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Leuplin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LHRH Analogs + Aromatase inhibitors</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Zoladex or Leuplin + Femara or Arimidex or Aromasin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed adenocarcinoma of the breast

          2. Female aged 20-75 years old at getting informed consent

          3. HER2 negative disease (IHC 0/1+ or 2+ with FISH negative)

          4. Documented estrogen receptor (ER) positive (&gt;=1% by IHC)

          5. Inoperative locally advanced or metastatic breast cancer at enrolment

          6. Performance status (ECOG): 0-1 at enrolment

          7. Life expectancy of at least 3 months from enrolment

          8. No prior systemic therapy for recurrent breast cancer (excluding hormone therapy)

          9. No prior neo and/or adjuvant chemotherapy with taxane or adjuvant setting with a
             disease-free interval from completion of the taxane treatment to metastatic diagnosis
             of &gt;= 12 months

         10. Patients with measurable lesion regarding with Response Evaluation Criteria in Solid
             Tumors(RECIST) criteria or who have evaluable lesion

         11. Patients with only bone lesion will be acceptable if the osteolytic lesion has a
             measurable soft tissue component by MRI or CT

         12. No influence on protocol treatment is considered in case prior therapy or examination.

         13. Adequate following organ function within 2 weeks before starting treatment. The latest
             examination results should be adopted and blood transfusion or treatment of
             hematopoietic factor drugs is not allowed 2 weeks before examination.

               -  Absolute neutrophil count &gt;= 1500 /mm3 or white blood cell(WBC) count &gt;= 3000
                  /mm3

               -  Platelets &gt;=10 x 10000 /mm3

               -  Hb &gt;= 9 g/dL

               -  Total bilirubin &lt;= 1.5 mg/dL

               -  aspartate aminotransferase(AST) and alanine aminotransferase(ALT) &lt;= 100
                  international unit(IU)/L

               -  Serum creatinine &lt;= 1.5 mg/dL

               -  Urine dipstick for proteinuria &lt;= 1+

         14. Written informed consent signed by patients before completing any treatment related
             procedure

        Exclusion Criteria:

          1. Prior therapy with bevacizumab

          2. Active infection requiring intrvenous antibiotics at enrollment or infection with
             active HBV and/or HCV.

          3. Pregnancy, lactetion or in case of potentialy pregnancy women Not mind contraception
             in trial period.

          4. Known hypersensitivity to bevacizumab or paclitaxel

          5. History of hemoptysis (&gt;= 2.5mL of bright red blood per episord).

          6. Use of disulfiram,cyanamide, carmofur or procarbazine Hydrochloride

          7. Patients with CNS metastases (except for not symptomatic)

          8. Persistent Grade &gt;= 2 sensory neuropathy at enrollment

          9. Grade 3 &gt;= hypertension (&gt;= 2 use of antihypertensive drug)

         10. Evidence with arterial thromboembolism (Cerebral infarction, Myocardial infarction) or
             history within 1 year prior to enrollment.

         11. Evidence withvenous thromboembolism (deep vein thrombosis, pulmonary embolism) or
             history within 1 year prior to enrollment.

         12. History of GI perforation and/or serious abdominal fistula within 1 year prior to
             enrollment

         13. Cases that the investigator judged as inappropriate as the subject of this clinical
             study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masakazu Toi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyoto University, Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigehira Saji, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fukushima Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japan Breast Cancer Research Group</name>
      <address>
        <city>Chuo-ku, Nihonbashi, Koami-cho</city>
        <state>Tokyo</state>
        <zip>1030016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

